Sage, Bio­gen tout an­oth­er PhI­II win for de­pres­sion pill, but dura­bil­i­ty con­cerns again cloud the drug's fu­ture

Sage Ther­a­peu­tics has put to­geth­er a con­stel­la­tion of piv­otal stud­ies ex­am­in­ing dif­fer­ent ways for how its ex­per­i­men­tal de­pres­sion drug could im­pact pa­tients’ symp­toms. Ear­ly Wednes­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER